Navigation Links
Senior Research Analyst Richard Evans Joins AVOS Life Sciences

MORRISVILLE, N.C., Sept. 12 /PRNewswire/ -- AVOS Life Sciences announced today that Richard Evans has joined AVOS as Vice President. His primary responsibility will be providing advisory services to companies in the prescription drug and biotech areas as well as selected investment assignments in capital markets. As an Institutional Investor (II) rated drug analyst, he will also have responsibility for AVOS' emerging portfolio of research products in the capital markets area.

"Richard brings us a senior level perspective on the drug industry," said Neil MacAllister, president of AVOS Life Sciences. "His background in capital markets complements our team and helps position AVOS as one of the strongest research and analysis firms in the pharmaceutical industry."

Mr. Evans has received several national awards from publications such as Bloomberg Markets magazine. He has been profiled in Barron's and Richard has also provided financial commentary for The Wall Street Journal, The New York Times, CNBC, CNN, and NPR.

Mr. Evans earned a master's degree in Public and Private Management from Yale University. He is also a Doctor of Veterinary Medicine, having received his degree from North Carolina State University.

"One of AVOS' strengths," continued MacAllister, "is our first hand experience gained through extensive consulting engagements delivering strategic, operational and financial insight to healthcare and drug companies. Richard's expertise in analyzing financial market conditions will greatly add to AVOS' ability to deliver actionable recommendations to our clients by providing them with a full understanding of capital market reaction."

AVOS Life Sciences, LLC is a healthcare consulting and research firm located in Morrisville, North Carolina, and New York, New York. The company helps clients understand the rapidly evolving pharmaceutical, biotechnology, medical device and diagnostic market segments, thereby assisting with strategic business development and investment decisions. AVOS' analytical tools are structured to assist with real-time decision-making in a dynamic environment.

AVOS' proprietary approach includes knowledge obtained through coverage of leading industry events, access to internal and external healthcare databases and the analysis and perceptive commentary of a network of experts such as leading pharma executives, global regulatory specialists, manufacturing and reimbursement consultants, and a team of analytical scientists.

For more information on Richard Evans joining AVOS, please contact

SOURCE AVOS Life Sciences, LLC
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. SecurePipe appoints two senior execs
2. Third Wave announces two senior management appointments
3. Senior Wisconsin stem-cell researcher leaves for Connecticut
4. Sonic Foundry names new senior vice president
5. The DIG System Nonradioactive Automated High-Throughput In Situ Hybridization: a Powerful Tool for Functional Genomics Research
6. Quantitation of the Protein MIA as a Marker for Chondrocytes in Research Samples
7. Control Your siRNA Research
8. Getting Started with MicroRNA Research
9. Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System
10. Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C
11. Research Organics
Post Your Comments:
(Date:6/23/2016)... 2016  The Prostate Cancer Foundation (PCF) is pleased to announce ... cures for prostate cancer. Members of the Class of 2016 were selected from ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... ... Supplyframe, the Industry Network for electronics hardware design and ... in Pasadena, Calif., the Design Lab’s mission is to bring together inventors and ... brought to market. , The Design Lab is Supplyframe’s physical representation of one ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... the trading session at 4,833.32, down 0.22%; the Dow Jones ... the S&P 500 closed at 2,085.45, down 0.17%. has ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ... BIND Therapeutics Inc. (NASDAQ: BIND ). Learn more ...
Breaking Biology Technology:
(Date:6/1/2016)... , June 1, 2016 Favorable ... Election Administration and Criminal Identification to Boost Global Biometrics ... recently released TechSci Research report, " Global Biometrics Market ... Competition Forecast and Opportunities, 2011 - 2021", the global ... by 2021, on account of growing security concerns across ...
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
(Date:5/12/2016)... 12, 2016 , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
Breaking Biology News(10 mins):